^
Association details:
| Biomarker: | ROS1 rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) + Visudyne (verteporfin) (Reactive oxygen species stimulant, Photosensitizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
YAP1 mediates initial cell survival during lorlatinib treatment via AKT signaling in ROS1-rearranged lung cancer
Published date:
10/26/2022
Excerpt:
...combinatorial therapy with verteporfin and lorlatinib was found to achieve significantly sustained tumor remission compared with lorlatinib monotherapy in vivo. These results suggest that YAP1 may mediate initial cell resistance to lorlatinib in KTOR71 cells. Thus, combinatorial therapy targeting both YAP1 and ROS1 may potentially improve the outcome of ROS1-rearranged NSCLC.
DOI:
https://doi.org/10.1111/cas.15622
